CHOP-VP_(16) 与 ProMACE-CytaBOM 方案治疗 NHL 疗效观察

Comparison Between Therapeutic Effects of CHOP-VP_(16)and ProMACE-CytaBOM Regimen in the Non-Hodgkin′s lymphoma

分别采用ＣＨＯＰ－ＶＰ１６方案对５２例和ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案对３０例非霍奇金淋巴瘤（ＮＨＬ）进行化疗，结果显示，ＣＨＯＰ－ＶＰ１６方案组的完全缓解率为５１．９％（２７／５２），总有效率为９２．３％（４８／５２）；ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案组的完全缓解率为４３．３％（１３／３０），总有效率为９０．０％（２７／３０）。两组的完全缓解率及总有效率比较，无显著性差异（Ｐ＞０．０５）。两组的主要毒副反应是骨髓抑制，ＣＨＯＰ－ＶＰ１６方案组和ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案组的白细胞下降（Ⅰ～Ⅲ度）分别为８２．７％（４３／５２）和８３．３％（２５／３０），但均无Ⅳ度下降发生，均无与毒性有关的死亡发生。结果表明，ＣＨＯＰ－ＶＰ１６方案治疗ＮＨＬ可以达到ＰｒｏＭＡＣＥ－ＣｙｔａＢＯＭ方案相近的疗效，且使用方便，毒副反应较轻。

82 patients with intermediatehigh grade non-Hodgin′s lymphoma entered to this study.52 cases received CHOP-VP_(16) regimen,the complete remission rate was 51.9%(27/52),the overall response rate was 92.3%(48/52).30 cases received ProMACE-CytaBOM regimen,the complete remission rate was 43.3%(13/30),the overall response rate was 90.0%(27/30).There was no significant difference((P>0.05) in response rate between the two groups.The main toxicity were myelosuppression,the leukocytopenia rate was 82.7% in CHOP-VP_(16) and 83.3% in ProMACE-CytaBOM(P>0.05).No fatal toxicity was encountered in both groups.The results demonstrate that CHOP-VP_(16) regimen is similar to ProMACE-CytaBOM reigmen in the therapeutic effect.